Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to 0.88.

  • Catalyst Pharmaceuticals' Equity Ratio rose 221.44% to 0.88 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.88, marking a year-over-year increase of 221.44%. This contributed to the annual value of 0.85 for FY2024, which is 358.03% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Equity Ratio is 0.88, which was up 221.44% from 0.88 recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Equity Ratio peaked at 0.91 during Q1 2021, and registered a low of 0.8 during Q4 2022.
  • Over the past 5 years, Catalyst Pharmaceuticals' median Equity Ratio value was 0.87 (recorded in 2024), while the average stood at 0.86.
  • Its Equity Ratio has fluctuated over the past 5 years, first skyrocketed by 713.01% in 2021, then crashed by 890.14% in 2022.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' Equity Ratio stood at 0.87 in 2021, then decreased by 8.05% to 0.8 in 2022, then increased by 3.16% to 0.83 in 2023, then increased by 3.58% to 0.85 in 2024, then rose by 2.4% to 0.88 in 2025.
  • Its Equity Ratio was 0.88 in Q3 2025, compared to 0.88 in Q2 2025 and 0.87 in Q1 2025.